Using a differential display strategy, we have isolated a eDNA corresponding to a mRNA which is induced by retinoic acid treatment of late gastrula Xenopus embryos, and much more strongly induced by retinoic acid and cycloheximide. The eDNA, designated X17C, encodes a novel mitogen-activated protein (MAP) kinase phosphatase of 378 amino acid residues which is only distantly related to other known MAP kinase phosphatases. In normal embryogenesis, the X17C mRNA is expressed after the midblastula transition and accumulates during gastrulation. In neurula and tailbud stage embryos the mRNA is localised in two domains, one in the anterior region of the embryo, and one at the tail tip. When expressed from synthetic mRNA injected into oocytes, the X 17C protein is found within the cytosolic fraction and not in the nucleus. The X17C protein dephosphorylates and inactivates Xenopus MAP kinase in oocytes stimulated to undergo maturation by progesterone. We indicate the application of X17C as a tool for interfering with MAP kinase signaling in somatic cells of embryos, using FGF receptor-mediated MAP kinase activation in animal cap explants.
Introduction
When retinoic acid is added exogenously to developing Xenopus embryos, a number of dysmorphogenic effects occur. Application of the retinoic acid during blastula and gastrula stages causes dose-dependent progressive loss of anterior mesodermal and neural structures, leading to truncation of the antero-posterior axis (Durston et aI., 1989; Sive et aI., 1990) . Externally this truncation is visible as the dose-dependent progressive loss of forehead, followed by cement gland, eyes and otic vesicle at increasing concentrations. These effects have been studied extensively, and it has been found that retinoic acid exerts effects by suppressing anterior mesodermal differentiation (which could secondarily affect anterior neurectoderm differentiation), and by direct effects on ectodermal differentiation (Cho and De Robertis, 1990; Cho et aI., 1991; Ruiz i Altaba and Jessell, 1991a; Sharpe, 1991; Sive and Cheng, 1991) . Furthermore, treatment of neurula stage embryos, when the CNS apparently develops independently of the axial mesoderm, causes disruption of the brain with the ectopic expression of more posterior cell types, although the anterior neural deficiencies are less extreme than when treatment with retinoic acid is begun earlier, at blastula or gastrula stages (Ruiz i Altaba and Jessell, 1991b) .
In developing Xenopus, exogenous retinoic acid affects the development of the tail as well as the head (Pfeffer and De Robertis, 1994) . Tail defects, characterised by severe truncation, can arise from relatively late treatments (stage 13 onwards). In addition to these effects of exogenous retinoic acid, analysis of the malformations induced by exposure to retinoids during post-gastrula development of Xenopus, the chick, the mouse, and in humans, has revealed craniofacial defects common to all these species (Sulik, 1988) . The defects are associated with abnormal cranial neural crest development, migration or differentiation. A prominent consequence is defective branchial arch development with subsequent malformations of branchial arch derivatives.
The dysmorphogenic effects of retinoic acid have led to the suggestion that retinoids may have morphogenetic or related roles in development and differentiation of Xenopus embryonic tissues. In support of this suggestion are the observations that (a) retinoids (all-trans-retinoic acid, 9-cis-retinoic acid and all-trans-retinoyl-,B-glucuronide) are present in gastrula embryos, unevenly distributed, and at concentrations sufficient for receptor activation (Creech Kraft et aI., 1994) , (b) retinoid receptors (RARs and RXRs) are expressed throughout early development, with specific tissue distributions (Ellinger-Ziegelbauer and Dreyer, 1993; Blumberg et aI., 1992; Marklew et aI., 1994) , and (c) exogenous retinoic acid causes the induction and ectopic expression of Hox genes in Xenopus embryos (Dekker et aI., 1992) .
In an attempt to define further genes that are primarily responsive to treatment of Xenopus embryos with retinoic acid, we have discovered that a novel mitogen-activated protein (MAP) kinase phosphatase gene is induced by retinoic acid treatment at post-gastrula embryonic stages. Induction is much greater when retinoic acid and cycloheximide are used in combination. This MAP kinase phosphatase is only distantly related to known MAP kinase phosphatases and defines a new sub-family of these regulators of the MAP kinase signaling pathway. The phosphatase gene expression in normal development is localised to the region of the branchial arches and the tip of the tail, regions to which RARy and RXR,8 gene expression is also localised, and which are characteristically sensitive to retinoic acid dysmorphogenesis in postgastrula embryos. The induction of the phosphatase gene expression suggests a mechanism for cross-talk between retinoid nuclear receptor signaling and the MAP kinase signaling pathway, and it is possible that upregulation of the phosphatase in those regions of the embryo that are sensitive to disruption of development by exogenous retinoids is responsible for aspects of the dystnorphogenic effects of retinoids. Here we report the isolation and properties of the novel MAP kinase phosphatase, and we indicate its potential as a reagent for probing signal transduction pathways downstream of receptor tyrosine kinases.
Results

Identification of differential reverse transcripts by differential display
We adopted the differential display technique (Liang and Pardee, 1992) as the means of identifying reverse transcripts of mRNAs that are either induced or repressed by all-trans retinoic acid treatment of stage 13 (late gastrula) Xenopus embryos. Cycloheximide was included in the treatment protocol in order to limit the responses to those not requiring protein synthesis. A number of differential reverse transcripts were evident in this initial display (Fig. lA) ; several of these were analysed but only one is discussed further here. The differential cDNA band indicated in Fig. lA was among those chosen for further study, being increased in amount by retinoic acid/cycloheximide treatment of late gastrula embryos. The band was excised from the gel, reamplified by PCR and cloned.
This initial cloned cDNA comprised mostly 3'-untranslated sequences. In order to isolate longer reverse transcripts, cDNA libraries were screened (see Experimental procedures). A cDNA clone containing the entire coding region was isolated from a cDNA library derived from untreated stage 17 (neurula) embryos. (Although the mRNA corresponding to this cDNA is inducible by the treatment, the mRNA is present at lower abundance in untreated embryos). The cDNA was designated X17C.
The protein encoded by X17C cDNA
The nucleotide sequence of X17C cDNA revealed a long open reading frame of 378 codons (Fig. IB) . Within its C terminal portion, the deduced protein sequence contains an active site motif (VHCLAGISRSV) with the sequence HCXAGXXR at its core (where X can be any amino acid), common to all protein tyrosine phosphatases (PTPases) (Charbonneau and Tonks, 1992) . The presence of this motif strongly suggested that the X17C protein is likely to be a PTPase, with the cysteine residue at codon 290 being involved in formation of a covalent phosphoenzyme intermediate (Pot et aI., 1991) . In addition, within the carboxy-terminal half of the primary sequence, the deduced protein showed several regions of high similarity to the human MAP kinase phosphatase CLlOO (Fig. lC ) (Keyse and Emslie, 1992; Alessi et aI., 1993) . On searching the Genbank database, CLl 00 was identified as the molecule with the greatest similarity to XI7C. The overall amino acid identity of X17C with CLlOO is 32% (57% similarity). The CLIOO phosphatase is a member of a family of dual specificity phosphatases, which are characterised by their ability to dephosphorylate the phosphothreonine and phosphotyrosine residues of activated MAP kinase, and which includes the MAP kinase phosphatase 3CH134 (which is also known as MKPl, and which is the mouse homologue of CLlOO) (Charles et aI., 1992) . Recombinant CLlOO and 3CH134 proteins have been shown to dephosphorylate and hence inactivate recombinant MAP kinase in vitro (Alessi et aI., 1993; Charles et aI., 1993; Zheng and Guan, 1993) . More recently identified mammalian members of the MAP kinase phosphatase family include PACI (Rohan et aI., 1993) , and B23 (Ishibashi et aI., 1994) . These proteins show extensive sequence identity with CLlOO. In addition, the Saccharomyces cerevisiae gene MSG5 encodes a dual specificity phosphatase having 22% amino acid identity with CLlOO. MSG5 is responsible for inactivating FUS3, a yeast homologue of MAP kinase (Doi et aI., 1994) . These similarities suggested that X17C is a MAP kinase phosphatase, but that it is significantly different, particularly in the amino-terminal portion of the primary sequence, from the other known MAP kinase phosphatases. There is no evidence of a membrane spanning region in X17C.
Induction ofX17C mRNA
The differential display technique used initially to isolate X17C cDNA revealed the apparent induction of X17C mRNA as an early response to treatment of embryos with retinoic acid plus cycloheximide. The inducibility of X17C mRNA by retinoic acid was further investigated and confirmed by a ribonuclease protection assay. Stage 13 embryos were treated with retinoic acid, or with retinoic acid plus cycloheximide, and the amount of X17C mRNA assessed by RNase protection. The cycloheximide treatment (Cascio and Gurdon, 1987) was B sufficient to eliminate at least 95% of protein synthesis in these embryos (data not shown). The results of this analysis ( Fig. 2A) show that X17C mRNA was present in untreated embryos, and that this basal level was increased by retinoic acid treatment (phosphorimager quantitation indicates an induction ratio of about four-fold). Treatment with retinoic acid plus cycloheximide resulted in greater induction than with retinoic acid alone, possibly through stabilisation of the X17C mRNA, or through an increase in X17C gene transcription brought about by cycloheximide. Cycloheximide alone resulted in a level of induction comparable with retinoic acid alone (not shown 
Time course and pattern of expression
The temporal changes of X17C expression in Xenopus embryos were analysed using the ribonuclease protection assay (Fig. 2B) . The egg contains a trace of X17C maternal transcript, barely detectable in this assay. At stage 9 (late blastula) transcript is clearly detectable. Thereafter the amount of transcript increases during gastrulation and neurulation, up to the tailbud stage.
We have performed preliminary investigations of the spatial pattern of X17C expression in normal Xenopus embryos by whole mount in situ hybridization (Fig. 3A) . In pre-neurula stages we did not detect clear localisation by in situ hybridisation (not shown). This is probably because during these stages the amount of X17C transcript is relatively low (see Fig. 2B ), and in addition the transcript may be too generally distributed to reveal clear localisation by in situ hybridisation. In neurula and tailbud embryos two domains of expression were evident, one anterior and one posterior. In tail bud embryos the anterior domain of expression includes the branchial arch region, and there is a hybridisation signal associated with the otic vesicle. The posterior domain of expression is confined to the tail tip. The pattern of X17C expression in neurula and tail bud embryos is similar to that of RARy (shown for comparison in Fig. 3B ) although the receptor expression does not show the otic vesicle association, and is not so tightly restricted to the tip of the tail. The pattern of X17C expression is also similar to, and included within, the pattern of RXR,B expression (our unpublished observations). RXR,8 is the only RXR receptor type that is present through late gastrula and neurula stages (Marklew et aI., 1994) . It is therefore likely that the induction of X 17C by retinoic acid at the late gastrula stage is mediated through RARylRXR,8 heterodimers. In retinoic acidtreated embryos the pattern of expression of X17C mRNA is also restricted to within anterior and posterior domains, but the morphology of these regions is abnormal (Fig.  3C ). Although the in situ hybridisation technique is not quantitative, it is evident that the staining in treated tailbud embryos is relatively intense, suggesting that upregulation of X17C expression by retinoic acid can persist during late stages of embryogenesis.
Translation ofX17C mRNA in injected oocytes
The protein encoded by X17C cDNA was investigated by injecting in vitro-synthesised mRNA into Xenopus oocytes. Fig. 4 shows a protein with an estimated size of about 41 kDa was synthesised in injected oocytes, consistent with the size predicted from the 378 codon open reading frame of the X17C cDNA (42036 kDa). This protein was contained within the soluble fraction of the oocyte homogenate. For the purposes of experiments which follow, we simply note that X17C mRNA is translated into a protein of the expected size in injected 00-cytes.
By manual enucleation of injected oocytes, the subcellular localisation of the X17C protein can be determined. Such an experiment (Fig. 5) , in which a thyroid hormone receptor was used as a positive control for nuclear localisation, demonstrates that by contrast with the nuclear receptor protein, X 17C protein is localised in the cytoplasm. Fig. 5 also shows that in the isolated cytoplasmic portions of oocytes that were manually enucleated, a new labelled band is apparent with a mobility a little faster than the X17C band evident in whole oocytes. The origin of this band is unclear, but it may be a break-down product of the full-length X17C polypeptide.
If the X17C protein is a MAP kinase phosphatase, as new new new Fig. 5 . Cytoplasmic localisation of X17C protein expressed in injected oocytes. Oocytes were injected either with 5 ng X17C mRNA, or with 5 ng Xenopus thyroid hormone receptor mRNA. The thyroid hormone receptor (TRal) is known to be concentrated in the nucleus (Old et aI., 1992) . Oocytes were radiolabelled as described in Fig. 4 , and were enucleated manually to generate nuclear and cytoplasmic fractions. Extracts of whole oocytes, cytoplasms, or nuclei are represented by w, c and n, respectively.
suggested by sequence homology, it should interfere with the phosphorylation (and hence aCtivation) of MAP kinase that occurs when oocytes are matured by progesterone treatment (Ferrell et aI., 1991; Posada and Cooper, 1992 ). This prediction was tested by assaying the MAP kinase activity of oocytes which had been injected with XJ7C mRNA and incubated with progesterone. Fig. 6A shows the results of an experiment where MAP kinase activation was assayed by an in-gel assay of protein phosphorylation. In this assay system, using Xenopus oocyte extracts, only one abundant myelin basic protein kinase band at about 42 kDa is resolved (which contrasts Western blot to detect MAP kinase and Cdc2 in extracts of oocytes injected with the wild-type or the mutated, XI7C(C290S), forms of X17C mRNA. The oocytes were injected either with about 2.5 ng of synthetic mRNA, or with ten-fold less (i.e. 0.25 ng, indicated by 1/10 in the figure). Oocytes were treated with progesterone (prog) where indicated. After incubation for 20 h, oocytes were homogenised, and extracts were analysed by Western blotting as described in Experimental procedures. (C) Effect of X17C on ERK2 in oocytes injected with synthetic X17C mRNA and ERK2 mRNA, incubated as described in Fig. 4 with radiolabelled methionine, and incubated in the presence or absence of progesterone to stimulate maturation. Where indicated, control experiments were carried out with the X17C(C290S) mutant of X17C (indicated by XI7Cmut in the figure), or with a mutant form of ERK2 in which the threonine and tyrosine residues that become phosphorylated are replaced by alanine and phenylalanine, respectively (indicated by AF ERK2 in the figure) . In this experiment, the amount of synthetic X17C mRNA that was injected was reduced to a low amount so that no labelled polypeptide corresponding to XI7C is visible on the autoradiograph of the SOS-polyacrylamide gel; this was to avoid obscuring the ERK2 bands (which co-migrate with X17C at about 42 kDa). The ERK2 bands are indicated by arrows corresponding to the phosphorylated (and hence slower migrating) and non-phosphorylated forms. (0) Assay for an effect of XI7C expression upon abundant oocyte phosphoproteins. Oocytes were injected with 2.5 ng of synthetic X17C mRNA. They were also injected with y_[ 32 pjATP to label phosphoproteins . After incubation for 20 h, homogenates were analysed by SOS-polyacrylamide gel electrophoresis and autoradiography. Oocytes were matured by inclusion of progesterone in the incubation medium, where indicated. The mutant form of X17C was expressed in oocytes where indicated, X 17C(C290S).
with mammalian ERK2 and ERKI at 42 and 44 kDa, respectively). Western blotting with an anti-MAP kinase antibody confirmed that this myelin basic protein kinase is MAP kinase (Fig. 6B) . Oocytes that were injected with X17C mRNA, and which hence expressed functional XI7C, did not show the accumulation of phosphorylated and activated MAP kinase that normally accompanies progesterone treatment. Expression of a mutant form of XI7C, in which the cysteine residue (codon 290) was replaced by a serine residue (this mutant is designated XI7C(C290S)) and which therefore would be expected to A c progesterone B be phosphatase-dead, had no effect on the phosphorylation and activation status of MAP kinase. The Western blot of Fig. 6B was also probed with an antibody to detect p34cdc2. In oocytes, p34cdc2 is phosphorylated on Thr-14 and Tyr-15 (Dunphy and Newport, 1989; Gautier et ai., 1989) . Oocyte maturation is accompanied by the activation of Cdc2 through its dephosphorylation (Dunphy and Newport, 1989; Ferrell et ai., 1991; Jessus et ai., 1991) . The upper band in p34cdc2 immunoblots of untreated oocytes presumably represents the tyrosine phosphorylated, cyc1in B-bound p34cdc2 component of pre- 
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MPF (Dunphy and Newport, 1989; Kumagai and Dunphy, 1991; Strausfeld et aI., 1991) . Loss of this upper band of p34cdc2 correlates with the appearance of HI kinase activity (Nebreda and Hunt, 1993) ; accordingly, progesterone-matured oocytes displayed only the lower p34cdc2 band. While X17C prevented the accumulation of phosphorylated MAP kinase, it did not affect the phosphotyrosine status of p34cdc2 in oocytes. In order to confirm further that X17C is a MAP kinase phosphatase and to assess its specificity, we investigated its action on the mammalian MAP kinase, mouse ERK2 (Leevers and Marshall, 1992) . Oocytes were injected with synthetic mRNA encoding ERK2. This mRNA was translated to give a polypeptide band at about 42 kDa on SDS-polyacrylamide gel electrophoresis. Conditions of injection and labelling were chosen so that only the ERK2 polypeptide was visible as a labelled product (Fig. 6C) ; this was to avoid obscuring the ERK2 with a band corresponding to X17C which has a similar mobility. Like the endogenous MAP kinase, the mouse ERK2 protein is also phosphorylated following progesterone treatment of the injected oocytes, hence slightly retarding its migration on SDS-polyacrylamide gel electrophoresis. Expression of functional X17C prevented the accumulation of phosphorylated ERK2 in progesterone-treated oocytes.
Specificity of the protein phosphatase X17C
From the foregoing, we concluded that X17C has the properties of a MAP kinase phosphatase as predicted from the sequence homology. 'Classical' MAP kinases such as ERKI and ERK2 are activated by phosphorylation of threonine and tyrosine within the signature sequence T-E-Y (Thr-183 and Tyr-185 for mammalian Fig. 7 . Effect of overexpression of X17C upon MAP kinase activation in response to bFGF in animal cap explants. Wild-type or phosphatasedead X17C was expressed in embryos by injection of 2.5 ng of synthetic mRN A into fertilised eggs at the two cell stage. Where indicated, embryos were injected with synthetic mRNA encoding a dominant negative FGF receptor, XFD (Amaya et aI., 1991) . Animal cap explants were taken at stage 8, and treated with bFGF (50 nglml) for 7.5 min, where indicated. The explants were then homogenised and analysed for MAP kinase activity by the in-gel assay. ERK2) (Marshall, 1995) . An indication of the specificity of X17C can be obtained from the observation that X17C expression in oocytes did not lead to dephosphorylation of Tyr-15 of p34cdc2. In order to investigate further the specificity of XI7C, the effect of its expression upon the popUlation of oocyte phosphoproteins was examined. Oocytes were injected with mRNA encoding either functional or mutant XI7C; these oocytes were radiolabelled by injection of y_[32P]_A TP, and in addition, samples of such oocytes were matured by progesterone treatment. The popUlations of [32P]-phosphoproteins in the oocytes were examined by SDS-polyacrylamide gel electrophoresis and autoradiography. The resulting autoradiograph (Fig. 6D) shows that the phosphoprotein population is altered dramatically by oocyte maturation, but that expression of functional X17C had no detectable effect. The resolution and sensitivity of this experiment was not adequate to reveal a band corresponding to MAP kinase, the known substrate of XI7C, but we conclude that X17C is inactive upon the abundant phosphoprotein species displayed by this experiment.
Effect ofX17C expression upon FGF-induced activation of MAP kinase in embryo explants
Much previous work on mesoderm induction in Xenopus has exploited the assay of inducers in animal cap explants. In this assay system FGF has the property of inducing mesodermal markers (Kimelman et aI., 1988; Slack et aI., 1988; Isaacs et aI., 1992) . Both ras and raf are known to be required for the signal transduction pathway leading from the FGF receptor to mesoderm formation in this system (Whitman and Melton, 1989; MacNicol et aI., 1993; LaBonne and Whitman, 1994; Gotoh et aI., 1995; LaBonne et aI., 1995; Umbhauer et aI., 1995) . Recently, MAP kinase activation has also been shown to be necessary in this signaling pathway (Gotoh et aI., 1995; LaBonne et aI., 1995; Umbhauer et aI., 1995) . Given the properties of X17C as a MAP kinase phosphatase, we have asked whether the activation of MAP kinase in response to exogenous FGF in animal cap explants would be disrupted by X17C expression. Fig. 7 shows the results of an experiment where the activation of MAP kinase in animal cap explants was assayed using the in-gel assay of myelin basic protein phosphorylation as the assay for MAP kinase activation. As expected from previous work, treatment of the explants with FGF resulted in the activation of MAP kinase. This activation was largely eliminated in caps expressing a dominant-negative, truncated form of the FGF receptor, designated XFD (Amaya et aI., 1991) . Functional X17C completely eliminated the activation of MAP kinase by FGF treatment of the explants. This demonstrates the activity of X17C in embryo explants, and indicates the application of X17C as a reagent for dissecting signaling pathways downstream of the FGF receptor, and other receptors whose signaling is mediated at least in part through MAP kinase. We have already demonstrated such an application in whole embryos, where over-expression of X17C from injected mRNA led to the formation of embryos characteristically deficient in posterior mesodermal derivatives, although head development was largely unaffected (Umbhauer et aI., 1995) .
Discussion
We have employed a differential display strategy to examine the response of late gastrula embryos to retinoic acid. It would be interesting to enumerate all of the primary changes in transcription brought about by retinoic acid treatment of the embryos. Although we cannot give a precise estimate, the results obtained with the particular (arbitrary) primers used in the analysis shown in Fig. 1 are representative, and typically with various primers such autoradiographs (not shown) displayed one or more differential bands. It is possible, therefore, to estimate that the proportion of responsive mRNAs may be as high as a few percent of the total number of mRNA types.
Among the induced mRNAs is X17C mRNA. We have presented evidence that X17C is a novel type of MAP kinase phosphatase. It is apparent that its mRNA is induced more strongly by retinoic acid plus cycloheximide than by retinoic acid alone (and in fact the mRNA is induced by cycloheximide alone). Although X17C is distinct from the CLlOO phosphatase, the induction by cycloheximide is a property shared by X17C mRNA in embryos and CLl 00 mRNA in cultured mammalian fibroblasts. CLlOO mRNA is induced by a number of stressrelated treatments in addition to cycloheximide (Keyse, 1995) , and it remains to be seen how far this applies also to XI7C. We have shown that the induction of X17C mRNA by retinoic acid treatment of late gastrula embryos results in an increase above a clearly detectable basal level. How the abundance of X17C protein changes in response to induction of the mRNA is currently unknown; this point will be approachable when antibodies to X17C become available.
The patterns of expression of X17C mRNA in late neurula and tailbud embryos are similar to those of RARy mRNA in such embryos. In tailbud embryos the whole mount in situ hybridisations of X17C mRNA reveal signals in the branchial arch region, and tail bud. The near coincidence of the patterns of X17C and RARy transcripts prompts the speculation that induction of X17C by retinoic acid may interfere with cell proliferation or differentiation, and thus induction of X17C may be responsible for the particular sensitivity of these regions to dysmorphogenesis in response to treatment with retinoic acid at post-gastrula stages. It is important to note that the characteristic defects in head development caused by retinoic acid treatment during stages up to and including gastrulation (Durston et aI., 1989) are likely to have different causes, such as failure of the anterior migration of mesoderm during gastrulation (Sive et aI., 1990) , from defects in the tail and branchial arch region which result from later treatment and which we suggest may be the result of interference with MAP kinase function. A further distinction is made between the various effects of different retinoic acid treatment regimes and the defects in posterior development (with little effect on head development) caused by injection of X17C mRNA into early embryos (Umbhauer et al., 1995) ; these posterior defects are consequences of the failure of normal mesodermal differentiation brought about by the interference with MAP kinase function.
The notion that induction of X17C by retinoic acid may be a mechanism for the late dysmorphogenic effects of the retinoids would gain support if it could be shown that retinoids actually reduce the amount of active MAP kinase in embryos. We have so far been unable to answer this point directly: this is partly due to the low level of MAP kinase activation observed throughout early embryogenesis: very much less than that found in animal cap explants treated with FGF.
We have investigated properties of X17C by expression in oocytes, and have employed progesterone treatment (at relatively high concentration, 50,ug/ml) as a means of maturing the oocytes. It is evident from data presented here that biochemical changes associated with maturation (p34cdc2 dephosphorylation, changes in abundant phosphoproteins) do in fact occur in oocytes expressing X17C even though these oocytes, at the time of analysis, possess very little active MAP kinase.
X17C protein is localised to the cytoplasm when expressed in oocytes. Although the cytoplasmic versus nuclear localisation observed in oocyte is not always representative of other cell types (Lemaitre et aI., 1995) , this result is strongly suggestive that X17C is cytoplasmic in those somatic cells in which it is expressed naturally. Sustained activation of MAP kinase, by MAP kinase kinase which is cytoplasmic (Lenormand et aI., 1993) , leads to translocation of the MAP kinase to the nucleus (at least in many cell types). Given this nuclear translocation of activated MAP kinase, and the observation that MAP kinase has targets both in the cytoplasm (for example phospholipase A 2 ) (Patte and Blanquet, 1992) , and in the nucleus (for example the transcription factors c-myc, ATF-2 and ELK-I) (Davis, 1993) , it has been proposed that cytoplasmic versus nuclear location of active MAP kinase may result in different end results on cell differentiation or proliferation (Keyse, 1995; Marshall, 1995) . It is significant that different MAP kinase phosphatases are localised in different compartments. By contrast with XI7C, the PAC-l (Rohan et aI., 1993) , and CLlOO (Keyse, 1995) phosphatases are nuclear, and hence these nuclear and cytoplasmic types of MAP kinase phosphatase may provide complementary tools for the analysis of this proposal. In particular, since MAP kinase activation occurs in the cytoplasm, the non-nuclear MAP kinase phosphatase is expected to eradicate all MAP kinase activation, whereas nuclear MAP kinase phosphatases are expected to eradicate only the active MAP kinase that is localised within the nucleus.
X17C mRNA is virtually absent before the midblastula transition in embryogenesis. The mRNA accumulates through gastrula and neurula stages. We have explored the use of X17C as a reagent by overexpressing it in early embryos injected with in vitro-synthesised mRNA, and then assaying the responsiveness of animal cap explants to FGF. The ability of X17C to prevent the activation of MAP kinase in response to FGF in these explants demonstrates the activity of X17C in somatic cells, and points to the potential of X17C as a reagent for investigating the roles of the MAP kinase cascade, as opposed to other pathways acting downstream of cell-surface receptors, in many aspects of proliferation and differentiation during development.
One reason for the emerging multiplicity of known MAP kinase phosphatases may involve different ranges of activities of the different phosphatases against different members of the MAP kinase family. Such differences in phosphatase specificity have yet to be fully investigated, but they should provide a biochemical approach for dissecting the roles of the different MAP kinase pathways. The different functional effects of nuclear versus cytoplasmic localisation of the phosphatases are also likely to be significant.
Experimental procedures
Materials
Cloned ERK2 cDNA, and the mutant form AF ERK2 (in which threonine-183 and tyrosine-185 are replaced by alanine and phenylalanine, respectively) were kind gifts of C.J. Marshall. Recombinant human bFGF was purchased from Gibco BRL. The dominant negative FGF receptor, XFD (Amaya et ai. 1991) , was a gift of J.e. Smith.
Differential display
To identify genes regulated by retinoic acid in Xenopus, embryos were treated as follows, at 20°C: (a) untreated controls; (b) retinoic acid (10 ,uM) treated for 3 h; (c) retinoic acid plus cycloheximide as follows: retinoic acid, 10 ,uM, and cycloheximide, 10 ,ug/ml, for 1 h, followed by a further 2 h with 10,uM retinoic acid in the absence of cycloheximide. This regime with cycloheximide effectively inhibited protein synthesis for the entire 3 h treatment period while maintaining viability (Cascio and Gurdon, 1987) . All treatments began at stage 13 of development. RNA was extracted as described (Umbhauer et aI., 1995) , for differential display RT-PCR (Liang and Pardee, 1992) . The 5' primer was the decadeoxynucleotide CTTGATTGCe. The 3' primer was the 13-mer deoxynucleotide TlICA. Differential bands were revealed by displaying radiolabelled PCR products from the different treatment regimes side-by-side following electrophoresis on a 6% denaturing polyacrylamide gel and autoradiography. Differential bands were excised from the gel, the DNA eluted and re-amplified by PCR and cloned in a plasmid vector. The initial cloned X17C cDNA comprised mostly 3' untranslated sequences. A full length cDNA clone was isolated by screening a cDNA library from stage 17 embryos, using the initial clone as hybridisation probe.
Plasmid construction
All constructs for in vitro transcription and mRNA injection were inserted into the pSP64T vector (Krieg and Melton, 1984) . Synthesis of capped mRNA with SP6 RNA polymerase was performed essentially as described (Smith, 1993) .
Oocyte and embryo injections
Xenopus oocytes were injected, and (where indicated) labelled with [35S]-methionine as described (Smith et aI., 1994) . After injection, oocytes were incubated for 18-24 h at 14°C before analysis. Embryos were obtained by standard techniques and staged as described (Nieuwkoop and Faber, 1975) . Injection, embryo manipulation, and preparation of animal cap explants were as described (Smith, 1993) .
Ribonuclease protection assay
The X17C antisense hybridisation probe was obtained by transcription of a cloned fragment of Xi7C cDNA of about 300 nucleotides in length, consisting mostly of a 3' portion of the open reading frame and extending over the stop codon. The full-length antisense probe was 395 nucleotides, and the protected fragment was 282 nucleotides. To confirm the integrity and quantity of RNA across samples, control assays were performed with an EF-la probe (Krieg et aI., 1989) . The developmental profile of this transcript is well characterised (trace amount at stage 9, large increase by stage 13, slightly higher level at stage 17). RNA extraction and RNase protections were as described (Amaya et aI., 1993) .
in situ hybridisation
The antisense Xi7C RNA probe was prepared from the same subclone as that used for RNase protection. A digoxygenin labelled antisense RNA was transcribed and used for whole-mount in situ hybridisation within albino embryos as described (Harland, 1991) .
In-gel kinase assay for MAP kinase
Levels of activated MAP kinase were measured using phosphorylation of myelin basic protein as a substrate, as described (Kameshita and Fujisawa, 1989) . Modifications were made to this method as follows. Protein extracts were prepared by homogenisation of oocytes or embryos in 10,u1 of phosphate-buffered saline per embryo or oocyte. Extracts were microcentrifuged for 1 min, run on a 10% SDS-PAGE gel at 25 rnA with 0.5 mg/ml myelin basic protein cast into the separating gel. SDS was removed from the gel by soaking in 20% propan-2-01 and 50 mM Tris, pH 8.0, for 1 h. The gel was then buffered by soaking in 50 mM Tris, pH 8.0, and 5 mM mercaptoethanol (buffer A), for 1 h. Subsequently, the proteins were denatured by soaking the gel in 6 M guanidine for 1 h. The gel was placed at 4°C, overnight, in buffer A with 0.1 % Tween-40. The activated kinase was detected using 60,uCi y_[32p]ATP as substrate. During this 3 h incubation the gel was buffered in 40 mM HEPES, pH 8.0, 5 mM magnesium chloride, 0.1 mM EGTA, 2 mM DTT, and 1O,uM ATP. Finally, the gel was washed extensively with 5% TCA and 1 % sodium pyrophosphate, dried and autoradiographed.
Western blotting
Oocytes were homogenised in 10,u1 per oocyte of icecold buffer containing 80 mM sodium ,a-glycerophosphate, pH 7.5, 20 mM EGTA, 15 mM MgCI 2 , 1 mM DTT, 1 mM PMSF, and 2,ug/ml each of leupeptin and aprotinin. The lysates were centrifuged at 10000 X g for 8 min, and the cleared supernatant was analysed by SDS-PAGE (5,u1 per lane) using 15% acrylamide according to the formula of Anderson et al. (1973) . Proteins were transferred to 0.2,um nitrocellulose sheets using a semidry blotting apparatus (Hoefer). The blot was blocked in TIBS (25 mM Tris, pH 8, 150 mM NaCl, 0.5% Tween-20) containing 4% milk powder, and then incubated with a mixture of anti-MAP kinase and anti-p34cdc2 antibodies in TTBS containing 1% milk powder. The Xp42/ Mpkl MAP kinase was detected using the rabbit antiserum 122 (Leevers and Marshal, 1992) provided by Sally Leevers and Chris Marshall. The monoclonal antibody 3El provided by Julian Gannon was used to detect p34cdc2. The immunoblot was developed with alkaline phosphatase staining.
